NEOPLASM study: Real-life use of lacosamide in patients with brain tumor-related epilepsy

Villanueva, Vicente; Saiz-Díaz, Rosa Ana; Toledo, Manuel; Piera, Ana; Mauri, J.A.; Rodríguez-Uranga, J.; López‐González, Francisco Javier; Gómez‐Ibáñez, Asier; Garcés, Mercedes; Aleja, Jesús González de la; Rodríguez‐Osorio, Xiana; Palao-Duarte, Susana; Castillo, Agustín Diez; Bonet, Macarena; Ruiz-Giménez, Jesús; Palau, Juan; Arcediano, Alberto; Toledo, María de; Gago, Ana

doi:10.1016/j.yebeh.2016.09.033

Cited by 36 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effectiveness of lacosamide in controlling seizures has also been investigated in studies that included patients with a range of brain tumor types, including gliomas as well as meningioma, medulloblastoma, and brain metastasis 16‐17,21 . Most of these studies were retrospective, patients had approximately 6 months of follow‐up, and the majority received lacosamide as add‐on therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Most of these studies were retrospective, patients had approximately 6 months of follow‐up, and the majority received lacosamide as add‐on therapy. Fifty percent responder rates of 66.3%‐84.6% and seizure freedom of 30.8%‐53.8% were reported at 6 months 16‐17,21 . Slight differences in effectiveness may be partly due to variations in trial design (prospective vs retrospective), tumor types, and tumor grade between the patient populations, as seizures secondary to low‐grade tumors may be more treatment‐resistant 22 …”

Section: Discussionmentioning

confidence: 99%

“…Lacosamide is a non–enzyme‐inducing AED indicated for the treatment of focal (partial onset) seizures in patients ≥4 years of age in the European Union and the USA 12,13 . Published data from retrospective and prospective studies has shown good tolerability and effectiveness of lacosamide in patients with BTRE 14‐18 . The primary objective of the current study was to evaluate the effectiveness of lacosamide added to one or two AEDs in the treatment of patients with BTRE, based on the 50% responder rate and patients’ global impression of change.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness and tolerability of lacosamide as add‐on therapy in patients with brain tumor–related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES)

et al. 2020

View full text Add to dashboard Cite

Objective: To evaluate the effectiveness and tolerability of lacosamide added to one or two antiepileptic drugs (AEDs) in the treatment of patients with brain tumor-related epilepsy (BTRE), and to evaluate patients' global impression of change and quality of life (QoL). Methods: This was a prospective, multicenter, single-arm, noninterventional study with a 6-month observation period (EP0045; NCT02276053). Eligible patients (≥16 years old) had active BTRE secondary to low-grade glioma (World Health Organization grade 1 and 2) and were receiving treatment with one or two AEDs at baseline. Lacosamide was initiated by the treating physician in the course of routine clinical practice. Primary outcomes were 50% responders (≥50% reduction in focal seizure frequency from baseline) and Patient's Global Impression of Change (PGIC) at month 6. Secondary outcomes included seizure-free status and Clinical Global Impression of Change (CGIC) at month 6, change in QoL (5-Level EuroQol-5 Dimension Quality of Life Assessment) and symptom outcomes (MD Anderson Symptom Inventory-Brain Tumor) from baseline to month 6, and Kaplan-Meier estimated 6-month retention on lacosamide. Safety variables included adverse drug reactions (ADRs). Results: Patients were recruited from 24 sites in Europe. Ninety-three patients received lacosamide (mean [standard deviation] age = 44.5 [14.7] years; 50 [53.8%] male; median baseline focal seizure frequency = five seizures/28 days [range = 1-280]), of whom 79 (84.9%) completed the study. At 6 months, 66 of 86 (76.7%) patients were 50% responders and 30 of 86 (34.9%) were seizure-free. Improvements on PGIC were reported by 49 of 76 (64.5%) patients. Based on CGIC, 52 of 81 (64.2%) patients improved. QoL and symptoms outcome measures remained stable. 648 | RUDÀ et al.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and tolerability of lacosamide as add‐on therapy in patients with brain tumor–related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition to levetiracetam, there have also been recent studies on lacosamide, mostly as an adjunctive therapy, in patients with brain tumor-related epilepsy, and similar seizure-freedom and seizure-reduction rates were seen [47,48,71]. There is currently a clinical trial evaluating the use of lacosamide for seizure prophylaxis in patients with highgrade glioma who have not had a seizure (NCT01432171).…”

Section: Antiepileptic Drugs (Aeds)mentioning

confidence: 99%

Tumor-related epilepsy: epidemiology, pathogenesis and management

Chen

Crawford

et al. 2018

J Neurooncol

View full text Add to dashboard Cite

show abstract

“…50 In patients with psychiatric comorbidities, valproic acid (titrated to a serum level of 70-100) and lacosamide (starting dose of 100 mg twice a day) are reasonable alternatives. 50,51 Monotherapy using phenytoin (despite its complicated drug interactions) and pregabalin has been described as well. 52,53…”

Section: Seizure Treatment In Patients With Brain Tumorsmentioning

confidence: 99%

Emergency Management of Epilepsy and Seizures

Bank

Bazil

2019

Semin Neurol

View full text Add to dashboard Cite

Seizure- and epilepsy-related complications are a common cause of emergency medical evaluation, accounting for 5% of 911 calls and 1% of emergency department visits. Emergency physicians and neurologists must be able to recognize and treat seizure- and epilepsy-related emergencies. This review describes the emergency evaluation and management of new onset seizures, breakthrough seizures in patients with known epilepsy, status epilepticus, acute symptomatic seizures, and acute adverse effects of antiepileptic drugs.

show abstract

NEOPLASM study: Real-life use of lacosamide in patients with brain tumor-related epilepsy

Cited by 36 publications

References 33 publications

Effectiveness and tolerability of lacosamide as add‐on therapy in patients with brain tumor–related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES)

Effectiveness and tolerability of lacosamide as add‐on therapy in patients with brain tumor–related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES)

Tumor-related epilepsy: epidemiology, pathogenesis and management

Emergency Management of Epilepsy and Seizures

Contact Info

Product

Resources

About